- G1 Therapeutics Inc (NASDAQ: GTHX) shares gain premarket after FDA approves COSELA (trilaciclib) for injection to decrease the incidence of chemotherapy-induced myelosuppression (damage to bone marrow) in adult patients when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small-cell lung cancer.
- COSELA is administered intravenously as a 30-minute infusion within four hours before the start of chemotherapy. It is expected to be commercially available in early March.
- G1 intends to initiate the post-approval clinical trial in 2022.
- The management will host a webcast and conference call at 8:00 a.m. ET today.
- Price Action: GTHX shares increased 36.5% at $42.18 in premarket trading on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
